Diagnosing the strengths and ills of AI in healthcare

Diagnosing the strengths and ills of AI in healthcare

Diagnosing the strengths and ills of AI in healthcare
AI systems, when properly trained and validated, can significantly reduce errors in medical diagnosis. (Shutterstock)
Short Url

One of the main advantages of artificial intelligence-supported diagnostics is the exceptional speed and accuracy it offers. AI systems can analyze vast amounts of medical data, including patient records, images and lab results, at a pace far exceeding human capabilities.

Speed can be crucial in emergencies, enabling faster decision-making and potentially life-saving interventions. Additionally, AI has proven its accuracy in diagnosing diseases, from common conditions to rare disorders, detecting anomalies that humans might miss.

Diagnostic errors are a persistent concern in healthcare. AI systems, when properly trained and validated, can significantly reduce these errors, as the elements of fatigue or cognitive bias do not exist in this equation, enhancing the overall quality of medical decisions.

By integrating patient information with extensive medical databases and clinical guidelines, AI can help identify potential issues and ensure no aspect is overlooked. This leads to more reliable diagnostics and treatment plans.

AI-supported diagnostics also facilitate the transition to personalized medicine. They can analyze a patient’s genetic makeup, lifestyle, and medical history to create personalized treatment plans.

This personalization ensures patients receive the most effective treatments with fewer side effects. It also improves medication management and dosage. 

AI has been applied in the fields of radiology and medical imaging, including X-rays, MRIs, and CT scans. Radiologists can benefit from AI assistance in detecting abnormalities, even in complex cases.

It is important to emphasize that AI is not intended to replace healthcare professionals. Instead, it should be viewed as a supportive tool. AI assists doctors and radiologists by providing data-driven insights, enabling them to make more informed decisions.

Saudi Arabia is investing heavily in AI-assisted diagnostics technology. Its “Eyenai” project is a collaborative effort involving the Saudi Data and AI Authority, King Khaled Eye Specialist Hospital, Lean Business Services, and the Saudi Company for Artificial Intelligence.

Developed by Saudi engineers and AI specialists, the project represents a pioneering solution in the field of ocular healthcare, using AI to accurately identify diabetic retinopathy. It relies on advanced analytics and smart algorithms to streamline and accelerate screening processes, overcoming challenges such as limited resources, examination time, and high costs.

Dr. Adi Al-Owaifeer, an ophthalmology consultant and head of the administrative committee for the Eyenai project, said that the initiative embodies the spirit of innovation and collaboration in Saudi Arabia’s healthcare system.

He also highlighted the importance of developing this solution to facilitate screening processes, increase accuracy, and treat as many individuals as possible.

The healthcare industry must work collaboratively with AI developers, regulators and policymakers to overcome these hurdles and pave the way for a more efficient, patient-centric system.

Abeer Alamrani

Microsoft recently introduced a suite of AI tools designed to help healthcare organizations access and enhance learning from data. In addition, Google has announced the development of an AI-powered tool to make it easier for professionals to search for health information.

Although AI can improve patient outcomes, increase efficiency, and reduce costs, integrating it into healthcare is not without its challenges.

First, AI systems require access to a vast number of patient records, raising concerns about privacy and security. Healthcare institutions must therefore implement robust measures to protect patient information from data breaches and cyberattacks.

Second, AI relies on high-quality, organized data for training and decision-making purposes. However, healthcare data can be unstructured, fragmented, or inconsistent, making it difficult for AI algorithms to derive meaningful insights.

Third, AI algorithms can inherit biases present in training data, which may lead to inaccurate decisions. Developing methods to identify and mitigate bias remains an ongoing challenge in AI ethics.

Fourth, obtaining regulatory approvals for AI-based medical devices and solutions can be a lengthy and complex process. Balancing innovation with regulatory compliance is a major challenge that healthcare companies must address.

Fifth, AI applications raise ethical questions, particularly regarding patient privacy, consent and transparency. Patients must be informed about how their data will be used and should have the right to opt out, and ethical guidelines should be developed.

Sixth, gaining the trust of healthcare professionals and patients is a significant challenge. AI systems must undergo strict clinical validation to prove their safety and efficacy, which can be a long and resource-intensive process.

Seventh, AI in healthcare requires substantial investments in technology, training and staffing. Healthcare providers must allocate resources for AI adoption and ongoing maintenance.

In conclusion, AI has the potential to bring about transformative changes to healthcare. However, addressing these challenges is essential to fully harness its benefits while ensuring patient safety, data security and ethical use.

The healthcare industry must work collaboratively with AI developers, regulators and policymakers to overcome these hurdles and pave the way for a more efficient, patient-centric system.

Abeer Alamrani is a machine learning, data analysis, and AI implementation consultant who helps organizations leverage AI to optimize operations, enhance decision-making, and achieve business goals.
 

Disclaimer: Views expressed by writers in this section are their own and do not necessarily reflect Arab News' point of view

Oman’s non-oil sector drives GDP to $27bn in Q1 2024

Oman’s non-oil sector drives GDP to $27bn in Q1 2024
Updated 2 min 22 sec ago
Follow

Oman’s non-oil sector drives GDP to $27bn in Q1 2024

Oman’s non-oil sector drives GDP to $27bn in Q1 2024

RIYADH: A rise in Oman’s non-oil activities boosted the country’s gross domestic product by 0.8 percent year-on-year to 10.45 billion Omani rials ($27.15 billion) in the first quarter of 2024. 

Preliminary data from the National Centre for Statistics and Information showed that non-oil activities recorded a value of 7.18 billion rials at the end of the first quarter, reflecting a 3.9 percent surge compared to the same period in 2023. 

This aligns with Oman’s economic outlook, which remains favorable, with real growth expected to reach 1.5 percent in 2024, driven by increased gas production and diversification efforts. 

Additionally, it supports the government’s efforts to advance governance and efficiency reforms, such as the plan announced in January to boost the economy through the launch of the Future Fund Oman by the Oman Investment Authority. This plan aims to attract foreign investment and bolster investments in local small and medium-sized enterprises. 

However, the data also revealed that crude oil activities amounted to 2.99 billion rials, a decrease of 4.4 percent compared to the same period last year. 

Similarly, natural gas activities dropped 0.1 percent year-on-year to 524.4 million rials in the first three months of 2024. 

Furthermore, total industrial activities recorded 2.18 billion rials, compared to 1.91 billion rials at the end of the first quarter of 2023. 


Iran’s president-elect Pezeshkian to be sworn in next month

Iran’s president-elect Pezeshkian to be sworn in next month
Updated 3 min 37 sec ago
Follow

Iran’s president-elect Pezeshkian to be sworn in next month

Iran’s president-elect Pezeshkian to be sworn in next month

TEHRAN: Iran’s Masoud Pezeshkian will be sworn in before parliament in early August as the Islamic republic’s ninth president, state media reported Sunday.
“The swearing-in ceremony of the president will be held on August 4 or 5,” said the official IRNA news agency, quoting Mojtaba Yosefi, a member of parliament’s presiding board.
“The president will have 15 days to present his proposed ministers to the parliament for a vote of confidence.”
Iranian presidents-elect are required to take an oath before parliament before officially taking office.
The swearing-in ceremony takes place after the president-elect receives an official endorsement by the Islamic republic’s supreme leader.
Iran’s president is not head of state, and the ultimate authority rests with the supreme leader — a post held by Ayatollah Ali Khamenei for the last 35 years.
Pezeshkian won a runoff election on Friday against the ultraconservative Saeed Jalili to replace president Ebrahim Raisi who died in a helicopter crash in May.
The 69-year-old reformist secured more than 16 million votes, around 54 percent, with Jalili winning more than 13 million, roughly 44 percent, out of about 30 million votes cast.
Turnout was 49.8 percent, Eslami added, up from a record low of about 40 percent in the first round.
On Sunday, Iranian newspapers published front-page photos of Pezeshkian and called for “unity” under the president-elect.


PROFILE: Dr. Mehmood Khan, Pakistan’s first scientist to be granted Saudi citizenship

PROFILE: Dr. Mehmood Khan, Pakistan’s first scientist to be granted Saudi citizenship
Updated 12 min 34 sec ago
Follow

PROFILE: Dr. Mehmood Khan, Pakistan’s first scientist to be granted Saudi citizenship

PROFILE: Dr. Mehmood Khan, Pakistan’s first scientist to be granted Saudi citizenship
  • Dr. Khan has served in key positions in corporate, medical and scientific fields in a career spanning three decades
  • Saudi Arabia has opened its citizenship to highly skilled professionals to attract and retain exceptional global talent

ISLAMABAD: Pakistani scientist Dr. Mehmood Khan this week became a member of a distinguished list of doctors, researchers, innovators and entrepreneurs from around the world who were granted Saudi citizenship, according to a list published by financial news portal Argaam.

An American national, Dr. Khan is currently the chief executive officer of the Hevolution Foundation, a non-profit organization that aims to increase the number of aging-related treatments, compress the timeline of drug development, and increase accessibility to therapeutics that extend a human lifespan.

A global non-profit organization headquartered in Riyadh with a North American hub, and an annual budget of up to $1 billion, Hevolution Foundation is the second largest geroscience funder with plans to open offices in other international locations. Geroscience is a field of biomedical research that seeks to understand how aging processes drive chronic diseases.

Dr. Khan was awarded Saudi citizenship after the kingdom opened its citizenship to highly skilled professionals as part of its Vision 2030, aiming to attract and retain exceptional global talent to enhance the kingdom’s economic and social development. A royal decree to this effect was issued in November 2021, allowing people belonging to specialized fields such as science, medicine, culture, sports and technology to apply for citizenship.

Dr. Khan, who earned his medical degree from the University of Liverpool Medical School in England, was also mentioned in the list of all the high achievers who received Saudi citizenship this week in Argaam. 

“So I grew up in England, actually haven’t had a chance to grow up in Pakistan,” Dr. Khan said during an interview in 2015 at OPEN Silicon Valley, an international organization of Pakistani entrepreneurs. “Proud to be Pakistani [though].” 

He advised budding corporate leaders and those aspiring to make a name for themselves in the medical field to take risks in life and pursue their passion. 

“Do take risks. Do not be afraid to take risks and do the best you can but pursue your passion,” he said. 

The Pakistani-American scientist has an impressive profile, having served in senior corporate and medical positions in a career spanning three decades. 

Dr. Khan has served as the chief executive officer at Life Biosciences Inc, vice chairman and chief scientific officer of global research and development at PepsiCo. from 2007-2019, and as the president of global research and development at renowned Japanese company, Takeda Pharmaceuticals, from 2003-2008.

He has served as director of the diabetes, endocrine and nutritional trials unit at the prestigious Mayo Clinic and Mayo Medical School from 2001-2003.

Dr. Khan is a fellow of the Royal College of Physicians and a fellow of the American College of Endocrinology as well.

He was the chairman of the US-Pakistan Business Council from 2016-2019 and continues to remain a board member of Reckitt Benckiser, a globally renowned British multinational consumer goods company.

Dr. Khan advised people aspiring to achieve senior positions in the corporate and medical fields to “reinvent” themselves.

“You cannot be the same that you were 30 years ago,” Dr. Khan told OPEN Silicon Valley. “If I was still doing what I learned 30 years ago, I couldn’t even practice medicine, let alone do what I do today.”


KSrelief carries out humanitarian projects in Lebanon, Indonesia

KSrelief carries out humanitarian projects in Lebanon, Indonesia
Updated 07 July 2024
Follow

KSrelief carries out humanitarian projects in Lebanon, Indonesia

KSrelief carries out humanitarian projects in Lebanon, Indonesia

The King Salman Humanitarian Aid and Relief Center has been actively involved in various humanitarian projects across Lebanon and Indonesia.

In Lebanon, KSrelief continued implementing the Al-Amal Charitable Bakery project, in its fourth stage, in the Akkar Governorate and Miniyeh District.

During the past week, the project distributed 150,000 bags of bread to needy families, benefiting 125,000 individuals, including Syrians, Palestinians, and the local host community in northern Lebanon. 

KSrelief also funded the ambulance service of the Subul Al-Salam Social Association in the Miniyeh District.

Over the last week, the service carried out 62 emergency missions, including transporting patients to and from hospitals and assisting victims of traffic accidents.

This support is part of a project aimed at enhancing ambulance transport services in Lebanon, including in areas with refugee communities.

In Indonesia, KSrelief concluded a volunteer medical project for pediatric heart surgery in Medan, from June 24 to July 1.

The project involved 27 volunteers from various medical specialties, who performed 25 open-heart surgeries. 


EU naval mission says it destroyed two drones in Gulf of Aden

EU naval mission says it destroyed two drones in Gulf of Aden
Updated 07 July 2024
Follow

EU naval mission says it destroyed two drones in Gulf of Aden

EU naval mission says it destroyed two drones in Gulf of Aden

ATHENS: The EU naval mission protecting ships crossing the Red Sea said its frigate Psara had destroyed two unmanned aerial vehicles in the Gulf of Aden on Sunday.
The Aspides mission began in February in response to drone and missile attacks on vessels by Iranian-aligned Houthi militants. The Houthis describe the attacks as acts of solidarity with Palestinians in Israel’s war in Gaza.
Other countries, including the United States, also have naval forces operating in the area.